Patented PDE10A inhibitors: novel compounds since 2007

Discovery of a Novel Class of Phosphodiesterase 10A Inhibitors and Identification of Clinical Candidate 2-[4-(1-Methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline (PF-2545920) for the Treatment of Schizophrenia†† Coordinates of the PDE10A crystal structures have been deposited in the Protein Data Bank for compound 1 (3HQW), 2 (3HQY), 3 (3HQW) and 9 (3HR1).

(2009) Patrick R. Verhoest et al.   JOURNAL OF MEDICINAL CHEMISTRY

Phosphodiesterase 10 inhibition reduces striatal excitotoxicity in the quinolinic acid model of Huntington's disease

(2009) Carmela Giampà et al.   NEUROBIOLOGY OF DISEASE

The Role of Phosphodiesterases in Schizophrenia

(2008) Judith A Siuciak   CNS DRUGS

Crystal Structure of the GAF-B Domain from Human Phosphodiesterase 10A Complexed with Its Ligand, cAMP

(2008) Noriko Handa et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Increased social interaction in mice deficient of the striatal medium spiny neuron-specific phosphodiesterase 10A2

(2008) Hiromi Sano et al.   JOURNAL OF NEUROCHEMISTRY

Preclinical Characterization of Selective Phosphodiesterase 10A Inhibitors: A New Therapeutic Approach to the Treatment of Schizophrenia

(2008) C. J. Schmidt et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Evaluating the antipsychotic profile of the preferential PDE10A inhibitor, papaverine

(2008) M. Weber et al.   PSYCHOPHARMACOLOGY